chrisvoncsefalvay/vaers-outcomes huggingface dataset:
my arm started paining me when I lay on it when I am in bed; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received COVID-19 Vaccine - Manufacturer Unknown, administration date Feb2021 (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 2021, outcome "unknown", described as "my arm started paining me when I lay on it when I am in bed".  Additional information: Consumer stated, "Here was patient question. Patient had the COVID Vaccine on February 9 months ago and couple months ago patient arm started painting me when I lay on it when I am in bed. It doesn't hurt to touch it and I wondered if that's a common side effect?"  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.  This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information is expected
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed the ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. In October 2010, a healthcare provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). In November 2011, the patient was treated by a physician for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization (dates unknown), physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events is considered to be not recovered. Additional information has been requested.
Information has been received from a healthcare professional concerning her niece of 10 year old who on 03-OCT-2008, was vaccinated with the first dose of GARDASIL vaccine.  The healthcare professional reported that on 03-OCT-2008, her niece had experienced hives after receiving the first dose of GARDASIL vaccine.  On unspecified date the patient had recovered.
Reported symptoms of redness, swelling and a feeling of hotness on Friday, November 9th - 48 hours after receiving the vaccine. RPh told her to monitor symptoms, if they persist, recommend MD visit. RPh checked back w/ pt 48 hours later.
Patient states that the vaccine was given higher than normally, in the shoulder area. It was very painful and the needle was not in all the way so she asked the Pharmacist to take the needle out and redo.  So the  pharmacist went a little lower in the arm and gave the shot. It was still very painful. Patient went to the doctor next day and the arm was examined by Dr. Dr suspects a tendon rupture from vaccine and ordered X rays. Still waiting to get x ray reports back. Patient was started on Prednisone and anti-inflammatory drugs.
Information has been received from a consumer via the Internet concerning her daughter who in August 2007, was vaccinated with GARDASIL.  Subsequently the patient had been sick ever since.  The patient had several hospital stays, saw a neurologist on a reg basis, and had been diagnosed with dysautonomia with orthostatic intolerance.  The patient experienced blackouts, chronic dizziness and took massive anxiety medicines.  She also experienced loose clumps of her hair, blurred vision, migraine headaches, nausea and panic attacks.  The patient's immune system had been so compromised that she had gotten MRSA (resistant staff) two times and was hospitalized for that.  The patient was also an honor student (straight A's) with a very bright future.  Her grades had dramatically dropped.  The reporter stated that they had to put her on a plan at school so that her attendance can not be held against her, and her teachers had to reduce her work load because she did not know from one day to the next whether she would be able to get out of bed.  At the time of reporting, the outcome was unknown.  Attempts are being made to verify the existence of an identifiable patient and reporter.  No further information is available.
Pt got 2 hives on front chest and 2 hives on his back - said he felt tingling in the area on his back prior to getting the shot.
I did not have an adverse reaction to the vaccine. I was diagnosed with polymyalgia rheumatica (PMR) in 08/2022.  It caused muscle pain and stiffness in my arms, legs and back. I take prednisone to help with my symptoms. I also was diagnosed with hernia recently.
Pt recvd 3 doses of Engerix-B vax & titers were checked 6 months p/last dose & titer result was 8.9, indicating a low pos response;
Constant/On and off headache since second vaccine was given (over a week now). Headache more in the frontal section of the head and in between eyes; however, it migrates and intensifies around my head. The headache depresses my mood and had to call off work. Been in bed due to headache since second dose was given.
pt suffered a sz the day p/the vax; pt turned blue, stopped breathing per mom; brought to ER & recvd 02 and was observed;
Patient was receiving first dose and as the nurse injected the needle and started to push the plunger, the vaccine squirted out of the patients arm completely. The patient requested to have the full first dose so an additional one was provided. No adverse reactions occurred.
Information has been received from a nurse referring to a patient of unknown gender and unknown age. The patient's pertinent medical history and drug reactions/allergies were not provided. On an unknown date, the patient received a dose of PROQUAD (rHA, lot # L046508, expiration date 17-MAY-2017, 0.5ml/frequency unspecified), which had been exposed to -14 Celsius degree for 6.5 hours (incorrect product storage), subcutaneously. No adverse effects were reported. Additional information is not expected as the physician does not want to be contacted.
Patient presented to Community Center at her scheduled appointment time to receive his 2nd dose of the COVID Pfizer vaccine. While being processed for 2nd dose vaccination, the client reported that she has a history of raised red papules to bilateral shoulders and noted similar presentation of red papules appeared on her chest about 1 week after vaccination. Client reports papules are still present. No associated itchiness or pain reported. Client states she followed up with a Nurse Practitioner who advised her to continue with vaccination. Client states she has been diagnosed with a skin condition of unknown name per client, and reports she has a prescribed cream that she is supposed to use. Client reports she has not used prescribed cream in the past.
Redness and itchiness in Deltoid area of injection (left)arm.  approx 6X3.    Started Saturday afternoon 2/20/2021. 8 Days after injection
Fatigue, chills, muscle pain, joint pain. Lasted about 1 1/2 day.
Pt was not vaxed-in contact w/two 8 mo old cousins who had been vaccinated w/OPV; Vax associated paralytic poliomyelitis confirmed by lab test type II viral isolate; occured in an unvaxed contact of a recently vaxed 8mo old;
RASH in the shape of measles in the arms; rash; still felt the lesions in the arms and they developed from red to purple until they slowly faded over between 3 to 4 months; This is a spontaneous report from a contactable consumer, reporting for himself. A 76-year-old male patient received the second dose of the pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) (PREVNAR 13) and the first dose of the varicella zoster vaccine rge (cho) (SHINGRIX), via unspecified routes of administration on 14Jan2020 at single doses for immunization. The patient's medical history and concomitant medications were not reported. The patient previously received the first dose of the pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) for immunization in May2019. On an unknown date, the patient experienced shape of measles in the arms, rash, and still felt the lesions in the arms and they developed from red to purple until they slowly faded over between 3 to 4 months. The clinical course was as follows: on the same day, he was administered with the second dose of pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein), he was administered with the first dose of the varicella zoster vaccine rge (cho) for Herpes Zoster. After the administration of the vaccines, he developed a rash that affected the knees and legs, arms in the elbows and inside the arms. It was further specified that the lesions were red and with the shape of a pencil eraser in the knees and legs and the shape of measles in the arms. He still felt the lesions in the arms and they developed from red to purple until they slowly faded over between 3 to 4 months. The clinical outcome of the events was unknown.   The batch/lot number for the vaccine, pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein), was not provided and will be requested during follow up.
Symptoms began midafternoon on 11/13/2017. They were muscle/neck pain, achy and chills all day and headache. Fever 101.2 at visit next day.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 50-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 16Dec2020 as dose 1, single (Batch/Lot number: unknown), on 07Jan2021 as dose 2, single (Batch/Lot number: unknown) and on 27Sep2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 49 years for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing). Concomitant medication(s) included: ADVIL [IBUPROFEN], start date: 21Jun2022, stop date: 23Jun2022,as other medication in 2 weeks. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive; (unspecified date) Positive; (28Jun2022) Negative; (29Jun2022) Negative; (30Jun2022) Negative; (01Jul2022) Negative. Therapeutic measures were taken as a result of vaccination failure, COVID-19.  Clinical course: Paxlovid was started in 22Jun2022 till 27Jun2022 for the treatment of COVID-19. Starting 04Jul2022 at 04:00 PM. 7 days after completing Paxlovid, the patient started having symptoms of fatigue. On 05Jul2022, the patient had sore throat, body aches. The patient did 2 home COVID tests, both were positive. Before this, the patient had 4 negative Covid tests starting on 28Jun2022 after the patient completed taking Paxlovid. The patient was Not recovered.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Based on the known safety profile of the vaccine  BNT162b2, a causal relation between the reported events Covid-19, Vaccination failure and the administration of the vaccine cannot be excluded.
racing heart rate around 48 hours after vaccine; Headache for 24 hours (mild); Intermittent shortness of breath for 48 hours; This is a spontaneous report from a contactable consumer, the patient. This 55 year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number: unknown),  dose  2 , single dose via an unspecified route of administration in the right arm on 19Jan2021 at 09:30 AM (at the age of 55 years-old) for COVID-19 vaccination. The patient was not pregnant.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Medical history included allergy to codeine. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, lot number: unknown ), dose 1, single dose via an unspecified route of administration in the right arm on 29Dec2020 at 03:45 PM.  Concomitant medications were not reported. The patient did not receive  any other vaccine within 4 weeks prior to the vaccine. The patient did not receive any other medication in two weeks. On 19Jan2021 at 05: 00 PM, the patient experienced mild headache for 24 hours and intermittent shortness of breath for 48 hours. On an unknown date, the patient had racing heart rate around 48 hours after vaccine. There was no treatment received for the events. The clinical outcome of events, mild headache and shortness of breath was recovered on an unknown date in Jan2021.  The outcome of the event racing heart rate was recovered on an unknown date. It was also reported that since the vaccination, the patient had not been tested for COVID-19.   The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.
a large lump where the vaccine was administered; This is a spontaneous report from a non-contactable nurse, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0168) via intramuscular route of administration in the left arm on 19May2021 at 10:00 (at the age of 56-years-old). The patient did not have any relevant medical history. The patient had no known allergies to medications, food, or other products. The patient did not receive any concomitant medications. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19May2021 at 10:00, the patient had a large lump where the vaccine was administered and two months later the lump was still there. The patient had no pain or discomfort but a noted lump. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event a large lump where the vaccine was administered was not resolved at the time of this report.  No follow-up attempts are possible. No further information is expected.
Pt given scheduled and ordered TDAP vaccine at 28 weeks gestation today. Given early 12 days after COVID-19 vaccine last received on 3/3/2021. Recommended that pt receive at 14 days per literature review online.  Pt notified HCT RN of receipt receipt of COVID vaccine after TDAP vaccine administered today. Chart reviewed and pt received vaccine within KP and documentation of COVID-19 vaccine not seen or noticed by HCT RN prior to administration. No adverse reactions noted s/p immunization. Doctors notified. Dr. to beside to assess pt. No reactions noted.
1st dose given Jan/Feb2021; wanting to complete the series; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (1st dose given Jan/Feb2021; wanting to complete the series) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (1st dose given Jan/Feb2021; wanting to complete the series). At the time of the report, PRODUCT DOSE OMISSION ISSUE (1st dose given Jan/Feb2021; wanting to complete the series) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   It was reported that employees received their first dose of the Moderna Covid-19 vaccine in Jan/Feb2021 and initially refused to get the second dose but now were wanting to complete the series.  There were four or five patients with no patient identifiers and vaccination details were not available to the reporter
I have been in menopause for 2 years, after the vaccine I got a period.  I called the nurse, she said that wasn't normal and referred me to an ob/gyn.  They did pap, sdt and biopsy of the uterine wall.  All tests came back negative.  I suggested that it was a side effect of the Coved vaccine and was told "that can't be it".  I have had another period sense then.
my skin is full of red docs; my skin is full of red docs; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown (booster), single for covid-19 immunisation. Relevant medical history included: "HIV" (unspecified if ongoing), notes: one year ago I discovered that I have HIV. The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Manufacturer unknown), for COVID-19 immunization. The following information was reported: SKIN DISORDER (non-serious), ERYTHEMA (non-serious), outcome "unknown" and all described as "my skin is full of red docs".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
pt recvd vax 16JUN93 & w/in 24 hrs devel severe lower back pain, lower abdo cramps described as pain resembling a miscarriage, nausea, projectile vomiting, diarrhea, h/a, fatigue, dehydration; seen in ER for dehydration;
Mild fever, fatigue, aches - slept for an additional 3-4 hours and symptoms had resolved
Six days after receiving the first does of the Pfizer vaccine, I started to experience pain and sensitivity in my right testicle. I was on my way to the ranch for a hunting trip and figured this pain would subside. The following day, Thursday 11/25/2021, the sensitivity and pain was the same. Throughout the rest of the trip, Saturday (11/26) through today, I have been experiencing discomfort. The sensitivity is still there but not as bad as before. But I am constantly having to readjust myself to provide relief.
On Jan 10, 2021 I received the second dose of the Pfizer vaccine into my left upper arm. The following day I woke up with my axillary lymph nodes swollen and extremely painful. I addition I did  have headache and fatigue. 90% of swelling has decreased on post day 3. Today at this time I am still having altered sensation and discomfort in left arm.
12/08/09 Swollen/red hives, itching, tender after right thigh DTaP injection. 12/11/09 much better today, child playful and bearing weight.
C/o sudden onset pain and weakness of right arm/shoulder.  States no relief with ice and ibuprofen.  States "shot was given very high up on right deltoid".
38-year-old female patient presenting to the emergency department for complaints of cough, headache, fever, body aches, and vomiting status post Materna vaccination.  Patient reports she received Materna second dose vaccination yesterday (2/24/21) at approximately 11 AM.  She started to experience symptoms yesterday approximately 5 PM that worsened this morning.  Patient has underlying history of asthma. ED DX: Asthma exacerbation, cough. Tx: Tylenol, albuterol, dexamethason 10 mg IM, atrovent.
fever; headache; chills; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever), HEADACHE (headache) and CHILLS (chills) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 033F21A, 018B21A and 010A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PYREXIA (fever), HEADACHE (headache) and CHILLS (chills). At the time of the report, PYREXIA (fever), HEADACHE (headache) and CHILLS (chills) had not resolved.            Concomitant drugs were not reported. Treatment medications were not provided.
Pain; This case was reported by a other health professional via call center representative and described the occurrence of pain in a 76-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced pain. On an unknown date, the outcome of the pain was unknown.   It was unknown if the reporter considered the pain to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient experienced pain after receiving 1st dose of vaccine. The reporter stated that patient wants to get her 2nd dose of Shingrix in the gluteal muscle, as the first one was very painful. The patient stated that she may not even get the 2nd dose if she cannot get it in the gluteal muscle. The reporter asked whether Shingrix can be given in the gluteal muscle. The reporter did not consent to follow up.
Information has been received from a nurse concerning a 22 year old female with sulfonamide allergy who on 19-MAR-2008 was vaccinated IM with a first dose of Gardasil (lot # not provided). Concomitant therapy included NUVARING. On 22-MAR-2008, three days later, the patient experienced shortness of breath and nausea. On an unspecified date, the patient recovered from shortness of breath and nausea. It is unknown if the patient sought medical attention. No product quality complaint was involved. Additional information has been requested.